Related references
Note: Only part of the references are listed.Allogeneic haemopoietic transplantation for acute myeloid leukaemia in second complete remission: a registry report by the Acute Leukaemia Working Party of the EBMT
Maria H. Gilleece et al.
LEUKEMIA (2020)
The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies
Jakob R. Passweg et al.
BONE MARROW TRANSPLANTATION (2019)
Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation
Cristina Toffalori et al.
NATURE MEDICINE (2019)
FLT3 Inhibitor Maintenance After Allogeneic Transplantation: Is a Placebo-Controlled, Randomized Trial Ethical?
Mark J. Levis et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Age >69 Years with Acute Myelogenous Leukemia: On Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Olle Ringden et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation
Giorgia Battipaglia et al.
BLOOD (2019)
Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
Jorge E. Cortes et al.
LANCET ONCOLOGY (2019)
Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion
Anna M. Paczulla et al.
NATURE (2019)
Outcomes of allogeneic haematopoietic stem cell transplantation from HLA-matched and alternative donors: a European Society for Blood and Marrow Transplantation registry retrospective analysis
Roni Shouval et al.
LANCET HAEMATOLOGY (2019)
The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia
Patrick Williams et al.
CANCER (2019)
Role of Donor Clonal Hematopoiesis in Allogeneic Hematopoietic Stem-Cell Transplantation
Mareike Frick et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia
Charles Craddock et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study
Naval Daver et al.
CANCER DISCOVERY (2019)
Recurrent genetic HLA loss in AML relapsed after matched unrelated allogeneic hematopoietic cell transplantation
Max Jan et al.
BLOOD ADVANCES (2019)
Very poor long-term survival in past and more recent studies for relapsed AML patients: The ECOG-ACRIN experience
Chezi Ganzel et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
Gerrit J. Schuurhuis et al.
BLOOD (2018)
Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without NPM1 Mutations
Sylvie D. Freeman et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells
Nimitha R. Mathew et al.
NATURE MEDICINE (2018)
Molecular Minimal Residual Disease in Acute Myeloid Leukemia
M. Jongen-Lavrencic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Long-term efficacy of reduced-intensity versus myeloablative conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: retrospective follow-up of an open-label, randomised phase 3 trial
Frederick Fasslrinner et al.
LANCET HAEMATOLOGY (2018)
Relative Impact of HLA Matching and Non-HLA Donor Characteristics on Outcomes of Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome
Francis Ayuk et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
Bifunctional PD-1 x αCD3 x αCD33 fusion protein reverses adaptive immune escape in acute myeloid leukemia
Monika Herrmann et al.
BLOOD (2018)
Immune Escape of Relapsed AML Cells after Allogeneic Transplantation
M. J. Christopher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
CD4 Donor Lymphocyte Infusion Can Cause Conversion of Chimerism Without GVHD by Inducing Immune Responses Targeting Minor Histocompatibility Antigens in HLA Class II
Peter van Balen et al.
FRONTIERS IN IMMUNOLOGY (2018)
Durable graft-versus-leukaemia effects without donor lymphocyte infusions - results of a phase II study of sequential T-replete allogeneic transplantation for high-risk acute myeloid leukaemia and myelodysplasia
Jeff K. Davies et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis
Sarah A. Buckley et al.
HAEMATOLOGICA (2017)
Selective graft-versus-leukemia depends on magnitude and diversity of the alloreactive T cell response
Cornelis A. M. van Bergen et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
Bart L. Scott et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Dose-Reduced Versus Standard Conditioning Followed by Allogeneic Stem-Cell Transplantation for Patients With Myelodysplastic Syndrome: A Prospective Randomized Phase III Study of the EBMT (RICMAC Trial)
Nicolaus Kroeger et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
A comparison between allogeneic stem cell transplantation from unmanipulated haploidentical and unrelated donors in acute leukemia
Simona Piemontese et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study
Alexander E. Perl et al.
LANCET ONCOLOGY (2017)
Precision oncology for acute myeloid leukemia using a knowledge bank approach
Moritz Gerstung et al.
NATURE GENETICS (2017)
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
R. M. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis
Sarah A. Buckley et al.
HAEMATOLOGICA (2017)
Integrating Proteomics and Transcriptomics for Systematic Combinatorial Chimeric Antigen Receptor Therapy of AML
Fabiana Perna et al.
CANCER CELL (2017)
The number of CD56dim NK cells in the graft has a major impact on risk of disease relapse following allo-HSCT
Luke Maggs et al.
BLOOD ADVANCES (2017)
Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States
Lori Muffly et al.
BLOOD (2017)
Optimal Practices in Unrelated Donor Cord Blood Transplantation for Hematologic Malignancies
Juliet N. Barker et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2017)
Prognostic Limitations of Donor T Cell Chimerism after Myeloablative Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
Eric Wong et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2017)
Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1
Jurjen Versluis et al.
BLOOD ADVANCES (2017)
Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Intermediate- or High-Risk Acute Myeloid Leukemia in Complete Remission: A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation
Florent Malard et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2017)
Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affinity retargeting platform
Muneera Al-Hussaini et al.
BLOOD (2016)
Hematopoietic stem cell transplantation for patients with AML in first complete remission
Jan J. Cornelissen et al.
BLOOD (2016)
The effect of donor characteristics on survival after unrelated donor transplantation for hematologic malignancy
Craig Kollman et al.
BLOOD (2016)
The Blood and Marrow Transplant Clinical Trials Network: An Effective Infrastructure for Addressing Important Issues in Hematopoietic Cell Transplantation
Amin M. Alousi et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA Trial
Charles Craddock et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Addition of 10-Day Decitabine to Fludarabine/Total Body Irradiation Conditioning is Feasible and Induces Tumor-Associated Antigen-Specific T Cell Responses
Marjan Cruijsen et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission
Andrew M. Brunner et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia
Charles Craddock et al.
HAEMATOLOGICA (2016)
An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation
Paul Ferguson et al.
HAEMATOLOGICA (2016)
Cord-Blood Transplantation in Patients with Minimal Residual Disease
Filippo Milano et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Assessment of Minimal Residual Disease in Standard-Risk AML
A. Ivey et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Ipilimumab for Patients with Relapse after Allogeneic Transplantation
Matthew S. Davids et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Genomic Classification and Prognosis in Acute Myeloid Leukemia
Elli Papaemmanuil et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia
Charles Craddock et al.
HAEMATOLOGICA (2016)
An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation
Paul Ferguson et al.
HAEMATOLOGICA (2016)
Mutational analysis of disease relapse in patients allografted for acute myeloid leukemia
Lynn Quek et al.
BLOOD ADVANCES (2016)
Treatment of Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapse after Allogeneic Stem Cell Transplantation with Azacitidine and Donor Lymphocyte Infusions-A Retrospective Multicenter Analysis from the German Cooperative Transplant Study Group
Thomas Schroeder et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
HLA Mismatch Is Associated with Worse Outcomes after Unrelated Donor Reduced-Intensity Conditioning Hematopoietic Cell Transplantation: An Analysis from the Center for International Blood and Marrow Transplant Research
Michael R. Verneris et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2015)
Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation
Shernan G. Holtan et al.
BLOOD (2015)
Are changes in HLA Ags responsible for leukemia relapse after HLA-matched allogeneic hematopoietic SCT?
A. Hamdi et al.
BONE MARROW TRANSPLANTATION (2015)
Prediction of Allogeneic Hematopoietic Stem-Cell Transplantation Mortality 100 Days After Transplantation Using a Machine Learning Algorithm: A European Group for Blood and Marrow Transplantation Acute Leukemia Working Party Retrospective Data Mining Study
Roni Shouval et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502
Steven M. Devine et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Busulfan-based conditioning regimens: not all partners are equal
Sergio Giralt
LANCET ONCOLOGY (2015)
Comparison of outcomes after unrelated cord blood and unmanipulated haploidentical stem cell transplantation in adults with acute leukemia
A. Ruggeri et al.
LEUKEMIA (2015)
Impact of pre-transplant co-morbidities on outcome after alemtuzumab-based reduced intensity conditioning allo-SCT in elderly patients: A British Society of Blood and Marrow Transplantation study
E. Nikolousis et al.
BONE MARROW TRANSPLANTATION (2015)
Effect of Postremission Therapy before Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia in First Complete Remission
Erica D. Warlick et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2014)
Comorbidity-Age Index: A Clinical Measure of Biologic Age Before Allogeneic Hematopoietic Cell Transplantation
Mohamed L. Sorror et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
HLA Match Likelihoods for Hematopoietic Stem-Cell Grafts in the US Registry
Loren Gragert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Pilot Study of Comprehensive Geriatric Assessment (CGA) in Allogeneic Transplant: CGA Captures a High Prevalence of Vulnerabilities in Older Transplant Recipients
Lori S. Muffly et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2013)
Who is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer?
Amin M. Alousi et al.
BLOOD (2013)
Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation
Christopher Bredeson et al.
BLOOD (2013)
Comparison of conditioning regimens of various intensities for allogeneic hematopoietic SCT using HLA-identical sibling donors in AML and MDS with <10% BM blasts: a report from EBMT
R. Martino et al.
BONE MARROW TRANSPLANTATION (2013)
Donor choice according to age for allo-SCT for AML in complete remission
F. Ayuk et al.
BONE MARROW TRANSPLANTATION (2013)
Randomized Study of 2 Reduced-Intensity Conditioning Strategies for Human Leukocyte Antigen-Matched, Related Allogeneic Peripheral Blood Stem Cell Transplantation Prospective Clinical and Socioeconomic Evaluation
Didier Blaise et al.
CANCER (2013)
Second Allograft for Hematologic Relapse of Acute Leukemia After First Allogeneic Stem-Cell Transplantation From Related and Unrelated Donors: The Role of Donor Change
Maximilian Christopeit et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study
Monique Terwijn et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Allogeneic Hematopoietic Stem-Cell Transplantation for Acute Myeloid Leukemia in Remission: Comparison of Intravenous Busulfan Plus Cyclophosphamide (Cy) Versus Total-Body Irradiation Plus Cy As Conditioning Regimen-A Report From the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation
Arnon Nagler et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Persistence and Efficacy of Second Generation CAR T Cell Against the LeY Antigen in Acute Myeloid Leukemia
David S. Ritchie et al.
MOLECULAR THERAPY (2013)
Reduced-Intensity Conditioning before Allogeneic Hematopoietic Stem Cell Transplantation in Patients Over 60 Years: A Report from the SFGM-TC
Patrice Chevallier et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2012)
Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation
Christoph Schmid et al.
BLOOD (2012)
Genomic loss of patient-specific HLA in acute myeloid leukemia relapse after well-matched unrelated donor HSCT
Cristina Toffalori et al.
BLOOD (2012)
Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)
Oliver C. Goodyear et al.
BLOOD (2012)
Comparative Outcomes of Donor Graft CD34+ Selection and Immune Suppressive Therapy As Graft-Versus-Host Disease Prophylaxis for Patients With Acute Myeloid Leukemia in Complete Remission Undergoing HLA-Matched Sibling Allogeneic Hematopoietic Cell Transplantation
Marcelo C. Pasquini et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Comparative Analysis of the Value of Allogeneic Hematopoietic Stem-Cell Transplantation in Acute Myeloid Leukemia With Monosomal Karyotype Versus Other Cytogenetic Risk Categories
Jan J. Cornelissen et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial
Martin Bornhaeuser et al.
LANCET ONCOLOGY (2012)
The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach
Jan J. Cornelissen et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts
Claudio G. Brunstein et al.
BLOOD (2011)
Long-term Outcomes Among Older Patients Following Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation for Advanced Hematologic Malignancies
Mohamed L. Sorror et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia
C. Craddock et al.
LEUKEMIA (2011)
Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis
Vikas Gupta et al.
BLOOD (2010)
In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia
Jaebok Choi et al.
BLOOD (2010)
Factors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia
Charles Craddock et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Effect of Age on Outcome of Reduced-Intensity Hematopoietic Cell Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission or With Myelodysplastic Syndrome
Brian L. McClune et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Hematopoietic Stem-Cell Transplantation for Acute Leukemia in Relapse or Primary Induction Failure
Michel Duval et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Prospective Evaluation of Allogeneic Hematopoietic Stem-Cell Transplantation From Matched Related and Matched Unrelated Donors in Younger Adults With High-Risk Acute Myeloid Leukemia: German-Austrian Trial AMLHD98A
Richard F. Schlenk et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis
Mary Eapen et al.
LANCET ONCOLOGY (2010)
Hematopoietic Cell Transplantation from an HLA-Mismatched Familial Donor Is Feasible Without Ex Vivo-T Cell Depletion after Reduced-intensity Conditioning with Busulfan, Fludarabine, and Antithymocyte Globulin
Kyoo-Hyung Lee et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2009)
Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia
Sarah Cooley et al.
BLOOD (2009)
Risk Score for Outcome After Allogeneic Hematopoietic Stem Cell Transplantation A Retrospective Analysis
Alois Gratwohl et al.
CANCER (2009)
Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission Systematic Review and Meta-analysis of Prospective Clinical Trials
John Koreth et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Loss of Mismatched HLA in Leukemia after Stem-Cell Transplantation.
Luca Vago et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide
Leo Luznik et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2008)
Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia
Richard F. Schlenk et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia
Eduardo Olavarria et al.
BLOOD (2007)
Hematopoietic cell transplantation-specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences
Mohamed L. Sorror et al.
BLOOD (2007)
Impact of cytogenetics on outcome of matched unrelated donor hematopoietic stem cell transplantation for acute myeloid leukemia in first or second complete remission
Martin S. Tallman et al.
BLOOD (2007)
Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?
Jan J. Cornelissen et al.
BLOOD (2007)
Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS)
Elihu Estey et al.
BLOOD (2007)
Deficient expression of NCR in NK cells from acute myeloid leukemia: evolution during leukemia treatment and impact of leukemia cells in NCRdull phenotype induction
Cyril Fauriat et al.
BLOOD (2007)
Allogeneic marrow stem-cell transplantation from human leukocyte antigen-identical siblings versus human leukocyte antigen-allelic-matched unrelated donors (10/10) in patients with standard-risk hematologic malignancy:: A prospective study from the French Society of Bone Marrow Transplantation and Cell Therapy
Ibrahim Yakoub-Agha et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation
Christoph Schmid et al.
BLOOD (2006)
Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using BLA-identical sibling donors in myelodysplastic syndromes
Rodrigo Martino et al.
BLOOD (2006)
Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia
S Tauro et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT
ML Sorror et al.
BLOOD (2005)
Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome
C Schmid et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Prognostic index for adult patients with acute myeloid leukemia in first relapse
DA Breems et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants
L Ruggeri et al.
SCIENCE (2002)
Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia:: long-term follow-up of 4 randomized studies
G Socié et al.
BLOOD (2001)
Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors.
MJ Laughlin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
